Safety and immunogenicity of the candidate malaria vaccines FP9 ME-TRAP and MVA METRAP in semi-immune adult males [MIM-OK-87312]

Safety and immunogenicity of the candidate malaria vaccines FP9 ME-TRAP and MVA METRAP in semi-immune adult males [MIM-OK-87312]

Bibliographic Details
Main Authors:	Kai, O, Mwacharo, J, Bejon, P, Lowe, B, Molyneux, S, Peshu, N, Marsh, K, Hill, A
Format:	Journal article
Published:	2005

Similar Items

Safety, immunogenicity and efficacy studies of candidate malaria vaccines FP9 and MVA encoding ME-TRAP in Kenyan children [MIM-PB-224908]
by: Bejon, P, et al.
Published: (2005)

A phase 2b randomised trial of the candidate malaria vaccines FP9 ME-TRAP and MVA ME-TRAP among children in Kenya
by: Bejon, P, et al.
Published: (2006)

Extended Follow-Up Following a Phase 2b Randomized Trial of the Candidate Malaria Vaccines FP9 ME-TRAP and MVA ME-TRAP among Children in Kenya
by: Bejon, P, et al.
Published: (2007)

Extended follow-up following a phase 2b randomized trial of the candidate malaria vaccines FP9 ME-TRAP and MVA ME-TRAP among children in Kenya.
by: Bejon, P, et al.
Published: (2007)

Extended follow-up following a phase 2b randomized trial of the candidate malaria vaccines FP9 ME-TRAP and MVA ME-TRAP among children in Kenya.
by: Philip Bejon, et al.
Published: (2007-08-01)

Immunogenicity of the candidate malaria vaccines FP9 and modified vaccinia virus Ankara encoding the pre-erythrocytic antigen ME-TRAP in 1-6 year old children in a malaria endemic area.
by: Bejon, P, et al.
Published: (2006)

Safety profile of the viral vectors of attenuated fowlpox strain FP9 and modified vaccinia virus Ankara recombinant for either of 2 preerythrocytic malaria antigens, ME-TRAP or the circumsporozoite protein, in children and adults in Kenya.
by: Bejon, P, et al.
Published: (2006)

Safety profile of the viral vectors of attenuated fowlpox strain FP9 and modified vaccinia virus Ankara recombinant for either of 2 preerythrocytic malaria antigens, ME-TRAP or the circumsporozoite protein, in children and adults in Kenya
by: Bejon, P, et al.
Published: (2006)

Safety and immunogenicity of the malaria candidate vaccines FP9 CS and MVA CS in adult Gambian men.
by: Imoukhuede, E, et al.
Published: (2006)

Safety and Immunogenicity of ChAd63 and MVA ME-TRAP in West African children and infants
by: Bliss, C, et al.
Published: (2016)

Safety and immunogenicity of heterologous prime-boost immunisation with Plasmodium falciparum malaria candidate vaccines, ChAd63 ME-TRAP and MVA ME-TRAP, in healthy Gambian and Kenyan adults.
by: Ogwang, C, et al.
Published: (2013)

Safety and immunogenicity of heterologous prime-boost immunisation with Plasmodium falciparum malaria candidate vaccines, ChAd63 ME-TRAP and MVA ME-TRAP, in healthy Gambian and Kenyan adults.
by: Caroline Ogwang, et al.
Published: (2013-01-01)

Safety and immunogenicity of an FP9-vectored candidate tuberculosis vaccine (FP85A), alone and with candidate vaccine MVA85A in BCG-vaccinated healthy adults: a phase I clinical trial.
by: Rowland, R, et al.
Published: (2013)

Safety, Immunogenicity and Efficacy of Prime-Boost Vaccination with ChAd63 and MVA Encoding ME-TRAP against Plasmodium falciparum Infection in Adults in Senegal.
by: Mensah, V, et al.
Published: (2016)

Safety, Immunogenicity and Efficacy of Prime-Boost Vaccination with ChAd63 and MVA Encoding ME-TRAP against Plasmodium falciparum Infection in Adults in Senegal.
by: Victorine A Mensah, et al.
Published: (2016-01-01)

Translating the immunogenicity of prime-boost immunization with ChAd63 and MVA ME-TRAP from malaria naive to malaria-endemic populations.
by: Kimani, D, et al.
Published: (2014)

It's OK if you don't love me /
by: Klein, Norma, 1938-1989 author
Published: (1977)

First field efficacy trial of the ChAd63 MVA ME-TRAP vectored malaria vaccine candidate in 5-17 months old infants and children
by: Tiono, AB, et al.
Published: (2018)

First field efficacy trial of the ChAd63 MVA ME-TRAP vectored malaria vaccine candidate in 5-17 months old infants and children.
by: Alfred B Tiono, et al.
Published: (2018-01-01)

Safety and immunogenicity of the candidate tuberculosis vaccine MVA85A in West Africa.
by: Brookes, R, et al.
Published: (2008)

Immunogenicity of High-Dose MVA-Based MERS Vaccine Candidate in Mice and Camels
by: Naif Khalaf Alharbi, et al.
Published: (2022-08-01)

Safety and immunogenicity of the candidate tuberculosis vaccine MVA85A in West Africa.
by: Roger H Brookes, et al.
Published: (2008-08-01)

Poxviral promoters for improving the immunogenicity of MVA delivered vaccines
by: Naif Khalaf Alharbi
Published: (2019-01-01)

The immunoepidemiology of malria [MIM-km-46728]
by: Marsh, K
Published: (2005)

Evaluation of the safety and immunogenicity of a candidate tuberculosis vaccine, MVA85A, delivered by aerosol to the lungs of macaques.
by: White, A, et al.
Published: (2013)

Correction: Safety and Immunogenicity of the Candidate Tuberculosis Vaccine MVA85A in West Africa
Published: (2011-01-01)

Correction: Safety and Immunogenicity of the Candidate Tuberculosis Vaccine MVA85A in West Africa.
by: Roger H. Brookes, et al.
Published: (2011-01-01)

alpha plus Thalassaemia protects against malaria-induced anaemia in children living on the coast of Kenya [MIM-SW-139920]
by: Wambua, S, et al.
Published: (2005)

You're ok, your dog's ok /
by: Schneck, Marcus, author 204639, et al.
Published: (1992)

Evaluation of the efficacy of chad63-mva vectored vaccines expressing circumsporozoite protein and me-trap against controlled human malaria infection in malaria-naive individuals
by: Hodgson, SH, et al.
Published: (2014)

Does injection use influence choice of and satisfaction with private health clinics? A user perspective [MIM-FK-216766]
by: Kombe, F, et al.
Published: (2005)

Development of MVA-d34 Tetravalent Dengue Vaccine: Design and Immunogenicity
by: Ramil R. Mintaev, et al.
Published: (2023-04-01)

Immunogenicity and efficacy of DNA/MVA HIV vaccines in rhesus macaque models
by: Lynette Siv Chea, et al.
Published: (2017-10-01)

A randomised, double-blind, controlled vaccine efficacy trial of DNA/MVA ME-TRAP against malaria infection in Gambian adults.
by: Moorthy, V, et al.
Published: (2004)

TRAP-based vectored vaccines are more immunogenic and protective than CSP-based vectors: Correlation of efficacy with long-lived memory T cells [MIM-AH-359251]
by: Dunachie, S, et al.
Published: (2005)

Evaluation of the Efficacy of ChAd63-MVA Vectored Vaccines Expressing Circumsporozoite Protein and ME-TRAP Against Controlled Human Malaria Infection in Malaria-Naive Individuals.
by: Hodgson, S, et al.
Published: (2014)

Highly stable and immunogenic CMV T cell vaccine candidate developed using a synthetic MVA platform
by: Marcal Yll-Pico, et al.
Published: (2024-03-01)

OK survey
by: Sherr-Ziarko, E
Published: (2017)

STAYING OK /
by: Harris, Amy Bjork, et al.
Published: (1985)

Ok, Boomer
by: Maximilian Steinbeis